Application of In Vivo Imaging Techniques for Monitoring Natural Killer Cell Migration and Tumor Infiltration

Prakash Gangadaran, Ramya Lakshmi Rajendran and Byeong-Cheol Ahn

1 Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Korea; prakashg@knu.ac.kr (P.G.); ramyag@knu.ac.kr (R.L.R.)
2 BK21 Plus KNU Biomedical Convergence Program, Department of Biomedical Science, School of Medicine, Kyungpook National University, Daegu 41944, Korea
3 Department of Nuclear Medicine, School of Medicine, Kyungpook National University Hospital, Daegu 41944, Korea
*
Correspondence: abc2000@knu.ac.kr

Received: 20 April 2020; Accepted: 20 May 2020; Published: 22 May 2020

Abstract: In recent years, the use of natural killer (NK) cell-based immunotherapy has shown promise against various cancer types. To some extent therapeutic potential of NK cell-based immunotherapy depends on migration of NK cells towards tumors in animal models or human subjects and subsequent infiltration. Constant improvement in the pharmacological and therapeutic properties of NK cells is driving the performance and use of NK cell-based immunotherapies. In this review, we summarize the molecular imaging techniques used in monitoring the migration and infiltration of NK cells in vivo at preclinical and clinical levels. A review of pros and cons of each molecular imaging modality is done. Finally, we provide our perception of the usefulness of molecular imaging approaches for in vivo monitoring of NK cells in preclinical and clinical scenarios.

Keywords: natural killer cell; in vivo tracking; migration; infiltration; bioluminescent; MRI; SPECT; PET

1. Introduction

Natural killer (NK) cells, a type of lymphocyte, were first reported almost four decades ago. They are granular in nature and are involved in immune-surveillance [1]. NK cells are integral to the innate immune system and therefore, act as the first-line of defense against invading pathogens [2]. NK cells are a promising cell type for adoptive cell therapy for several reasons. They do not require priming or prior sensitization to interact with and kill tumor cells [3,4]. NK cells have a proven ability to detect neoplastic cells in the body, as demonstrated by accumulating evidence over the last four decades. The resulting knowledge about NK cell regulation has improved the effectiveness and safety of the NK cell treatment. Migration of NK cells into tumors is a critical factor for elimination of the aberrant cells [5]. Limited efficiency of NK cells depends on the number of malignant cells that are killed by one NK cell and migration speed of NK cells. These limitations hamper the efficacy of the immune system to the tumor. The tumor microenvironment poses a major challenge to clinical applications of the NK cell due to immune suppressive signals that disturb both tumoral infiltration of NK cells and their activation at the tumor site [6]. However, recent studies have reported the heterogeneity of NK cell populations and variability in host responses to NK cell therapy [7]. Isolation and ex vivo amplification of the most therapeutically efficient NK cell subpopulation from the total population of NK cells from a patient with a tumor could allow better treatment.
Oncologists have questioned the tumor homing capability of ex vivo expanded NK cells, and their cytotoxicity in the tumor microenvironment. Over the past 20 years, only a few clonal NK-cell lines had been established (NK-92, NK-YS, KHYG-1, NKL, NKG, SNK-6 and IMC-1). The NK-92 line was derived from peripheral blood of 50-year old Caucasian man with non-Hodgkin’s lymphoma [8]. NK-92 cells are cytotoxic to various cancer cell types in vitro and in vivo. These cells are the only ones to date that have a clinical benefit and minimal side effects following their infusion into patients with advanced cancers [9,10]. Efficient immunosurveillance of NK cells requires cell motility and constant surveillance of tumor cells [11,12]. NK cells have an extremely heterogeneous range of migratory behaviors at different stages of development [13]. Fibronectin facilitates the migration of NK cells to tumors and chemokines are important in the recruitment of NK cells [14,15]. Several strategies have significantly increased NK cell migration and infiltration within tumor tissues [16,17].

Realizing the therapeutic potential of NK cells requires more knowledge of cell characteristics. Non-invasive in vivo real-time imaging of NK cells in animal tumor models and human subjects become important in this context to determine the NK treatment success and efficacy. In this review paper, we discuss molecular imaging techniques used to evaluate the migration and infiltration of NK cells. We also discuss the advantages and shortcomings of approach. Finally, we review the development of the technologies and designs that has led to the currently available sophisticated methods with specific in vivo examples.

2. Non-Invasive In Vivo Imaging Modalities

Precise in vivo imaging of NK cell migration is extremely useful for basic and advanced biomedical researches, and for practical applications. Optical imaging methods are especially well-suited for visualizing infused cells in preclinical animal studies as they are very sensitive and non-invasive [18,19]. Optical imaging that uses visible light can provide multiplex imaging results by analyzing special properties of photons. Both tumor and NK cells can be visualized simultaneously in an animal model. These images have been used by scientists for research and by physicians for diagnosis and cell-based treatments [20,21]. Optical imaging is a powerful method for in vivo real time cell tracking in small animals over time without animal sacrifice [18,22]. Even-though optical imaging possesses many advantages but has the disadvantage of limited tissue penetration depth and it is not suitable for clinics [23]. Optical imaging can be of two main types—fluorescent and bioluminescent imaging. Fluorescent imaging needs external light source to activate protein molecules. Fluorescent dye used for cell labeling may show non-cell-associated signals in tissues or organs even after death of the labeled cells [24]. On the other hand, bioluminescent imaging captures a natural light produced via the interaction between bioluminescent proteins and their substrates such as firefly luciferase and D-luciferin. Bioluminescent imaging requires genetically modified luciferase and this imaging is also not suitable for clinics [25].

Advantages of nuclear imaging using radionuclides are excellent sensitivity and no depth limitation [26]. Compared to optical imaging, nuclear imaging is adept at visualizing deeply located organs [18,27,28]. Therefore, nuclear imaging could be a good candidate for in vivo tracking NK cells and evaluating their therapeutic efficacy in large animals and even in humans. Nuclear imaging also has its own disadvantages such as ionizing radiation exposure, long scan time [20,29]. Some nuclear imaging techniques such as single-photon emission computed tomography (SPECT) or positron emission tomography (PET) can be used to obtain three-dimensional tomographic images data. Magnetic resonance imaging (MRI) has high resolution with no ionizing radiation unlike nuclear imaging. MRI also has disadvantages such as a lower sensitivity than PET or SPECT and an expensive cost [30,31].
Two is better than one, so dual or hybrid imaging using nuclear imaging combined with anatomical imaging, such as computed tomography (CT) or MRI, are clinically available. Therefore, allowing us to examine the functional and also structural imaging at the same time. The hybrid technology allows accurate localization of the NK cells in subjects; MRI with an advantage of excellent resolution for anatomical structures has been successful in this regard as nuclear imaging has low anatomical resolution (PET/SPECT) [32–34]. Advancement in the field of imaging technologies are encouraging and forthcoming hybrid imaging systems will reveal accurate in vivo kinetics of NK cells in the near future.

3. In Vivo Monitoring of NK Cell Migration and Infiltration into a Tumor by Molecular Imaging

Development of NK cell-based cytotherapy requires a clear understanding of migration followed by the infiltration of NK cells to tumors and an ability to quantitatively analyze their in vivo fate after administration. Noninvasive in vivo imaging modalities for the administered NK cells might permit the comprehensive understanding of the in vivo therapeutic effects of NK cells for diseases including cancerous diseases by providing accurate data of the in vivo distribution and kinetics of the cells. Recent advancements in in vivo molecular imaging permit the recognition of simultaneous multiple biological processes within living organisms [20]. Translation from in vitro to in vivo settings allows real-time visualization of NK cells in animal models and humans [21,27,28,32,35].

Lim et al. studied the in vivo cytotoxicity effects of NK92MI cells labeled with anti-human CD56 antibody coated QD705 (near infrared [NIR]-emitting fluorescent quantum dot) using melanoma tumor-bearing mice. NK92MI cells were retained in the tumors 24 h following intratumor injection as shown tumor by fluorescence imaging. Localization of NK cells in the tumor is one of requisites for antitumor activity. The observed reduction in tumor size suggested the potential therapeutic effect of the administered NK cells. Viability and therapeutic effect of the NK cells were not influenced by the fluorescence imaging agent to NK cells [36]. However, other studies used techniques of lipofection or electroporation to label genetically modified NK cells with iron-oxide contrast agents for MRI [37,38]. However, delivery of the iron-oxide contrast agents into the NK cells by electroporation damages the cell membrane and decreases cell viability [37]. In addition, imaging of ferumoxides labeled NK cells with MR technology showed relatively low sensitivity [38]. Jang et al. demonstrated the controlled migration of NK cells towards human B cell lymphoma using an external magnet in a mouse model. NK92MI cells were labeled with cy5.5-conjugated Fe3O4-SiO2 core/shell nanoparticles to control the migration of the NK cells in the external magnetic field. Fluorescence imaging revealed migration control of NK cells by the technique. The NK cells loaded with nanoparticles migrated to the tumor and infiltrated into the tumor up to 17-fold greater compared to the control. The labeling procedure did not affect the killing activity of the NK cells [39]. Bioluminescent imaging is a promising method for long term NK cell tracking in small animals because its signal will not be diluted by cell division and signal disappears after death of the cells [21] but inverse in NIR dye labeling [39].

Wennerberg et al. demonstrated NK cell migration using a NIR lipophilic dye (DiR) in a xenograft mouse model. The study was based on the knowledge that NK cells express chemokine receptor chemokine receptor 3 (CXCR3), the receptor for CXC ligand 10 (CXCL10). To exploit this chemoattraction, the authors transfected a human melanoma cell line with CXCL10 then implanted the cells into mice. Fluorescence imaging revealed that intravenously injected DiR-labeled NK cells migrated and infiltrated to melanoma expressing CXCL10 rather than to negative melanoma tumor [17]. Tavri et al. described the migration of genetically modified NK cells (NK-92-scFv(MOC31)-zeta cells; scFv: humanized single-chain Fv antibody fragment) by labeling the NK cells with another NIR lipophilic dye (DiD). Fluorescence imaging revealed the migration of the NK cells to tumor-associated epithelial cell adhesion molecule (EpCAM) expressing human prostate cancer cells in a mouse model 90 min-post intravenous injection of the NK cells. Delayed fluorescence imaging revealed that more NK cells migrated to the tumor at 8 and 24 h [40]. Overall, the direct labeling has become a strategy of choice among researchers due to its simplicity and feasibility, even though it has some flaws [18]. Uong et al. demonstrated ex
vivo-expanded NK cell migration using ESNF13 NIR fluorophores in the metastatic and xenograft mouse model. Fluorescence imaging successfully visualized intravenously injected ESNF13-labeled NK cells migrating to the tumors. Fluorescence imaging revealed migration of the NK cells to lung metastatic and xenograft breast cancer within 30 min, with the strongest signal was observed at 30 min (lung metastasis) and at 1 h (xenograft) [41]. Lee et al. developed an antibody-based NK-cell–homing protein, named NK-cell–recruiting protein-conjugated antibody (NRP-body). They demonstrated the infiltration of NK cells to tumors in an orthotopic and metastatic pancreatic cancer mouse model. Two weeks post-injection with cancer cells, NRP-body and control-body were administered. NK cells were then intravenously injected into the mice. Fluorescence imaging at 5 days post-injection of NK cells showed that mice injected with NRP-body showed significantly higher NK cells infiltration to orthotopic and metastatic pancreatic cancer than control-body injected mice and reduced the tumor burden and size [42].

Zhu et al. transduced the firefly luciferase (Fluc) gene into NK cells (NK/Fluc) and used bioluminescent imaging to track the migration of intravenously injected cells towards the anaplastic thyroid cancer (CAL-62) in mouse models with lung metastasis or xenograft. Imaging revealed that NK/Fluc cells migrate and infiltrate into the lung tumor within 1 h, remain there for up to 24 h and then reduced in number at 48 h. Furthermore, in a xenograft model, intravenously injected NK/Fluc cells migrated to the lung within 1 h and then migrated to the xenograft tumor within 3 h. The cells remained in the tumor for up to 24 h, with reduced cell number detected at 48 h [21]. Optical imaging features low spatial resolution and poor tissue penetration, which limits its possibility of clinical translation [17, 21, 36, 39].

Other researchers investigated the migration of NK-92-scFv(MOC31)-zeta cells to EpCAM-positive prostate cancers in a rat model using MRI. Ferumoxide was used for labeling to permit their tracking. These cells and ferumoxide-labeled EpCAM-targeting NK-92-scFv(MOC31)-zeta cells were intraperitoneally injected in a prostate tumor-bearing rat. Imaging demonstrated marked negative tumor enhancement 1- and 24-h post-injection of the labeled NK cells. The signal remained unchanged at 1- or 24-h post-injection of the labeled NK-92 cells. The observations clearly indicated that NK-92-scFv(MOC31)-zeta cells migrated to the tumor site killed tumor cells [38]. One flaw in the experimental design was that the long-term imaging was not performed. Another study using MRI demonstrated migration of genetically modified NK-92 (NK-92-scFv(FRP5)-zeta) cells into HER2/neu positive mammary tumors. scFv(FRP5)-zeta is a chimeric antigen receptor specific to the tumor-associated ErbB2 (HER2/neu) antigen. NK-92-scFv(MOC31)-zeta and parental NK-92 cells labeled with ferumoxide and ferucarbotran were intravenously injected into mice harboring mammary tumors in the mammary fat pad. Imaging revealed migration of NK-92-scFv(MOC31)-zeta cells to the tumor. While labeling did not affect the migratory properties of NK cells, electroporation caused impairment of cell viability [37]. Mallett et al. also used MRI to visualize the migration of KHYG-1 human NK cells to prostate tumors in nude mice. Ultra-superparamagnetic iron oxide labeled KHYG-1 cells were subcutaneously injected into the tumor region, this labeling method did not affect the cell viability of KHYG-1 cells. A limitation of the study was that macrophages might take up the iron, which was released from the labeled NK cells [34].

A recent study investigated the migration of NK cells by labeling them with $^{19}$F perfluorocarbon and assessing their tumor infiltration in neuroblastoma mouse model. MRI revealed cell infiltration into tumors at day 0 and 2. The labeled cells were also injected via the same route into mice harboring human mantle cell lymphoma. MRI revealed tumor infiltration of the cells at days 0, 1, 3 and 8. Upon subcutaneous injection of labeled cells into melanoma-bearing mice, tumor infiltration was observed on days 0, 1, 3, 7, 10 and 15 [33]. The labeling procedure did not affect the expression of NK cell cytotoxicity mediators (IFNɣ and granzyme B) and cytotoxicity as well. $^{19}$F does neither decay nor require phagocytosis to enter cells. It is a component of the FDA approved drugs and long safety records in humans [33, 43]. One obvious limitation was non-detectability of $^{19}$F-labeled NK cells in the lungs due to signal loss via multiple air-tissue interfaces [33]. A new study investigated the infiltration
of murine NK cells (LNK) to tumors using MRI by labeling LNK cells with ferumoxytol and tumor infiltration of the NK cells was assessed in mice. Ferumoxytol-LNK cells were injected through hepatic arterial or venous routes in a rat bearing hepatocellular carcinoma. MRI results revealed that LNK cells injected via both routes migrated to the tumor. The hepatic arterial infusion increased the NK cell migration efficacy and decreased the tumor volume compared to intravenous injection [44]. Another study demonstrated the infiltration of SPIO labeled NK-92MI cells into tumors using MRI. The NK cells were infused through the hepatic artery. MRI revealed a higher signal in the tumor than in normal liver tissue, which clearly showed that the NK cells infiltrated to the tumor [32]. MRI has limitations of low sensitivity and slow acquisition time. In addition, ferumoxide labeling can cause cellular damage, which can induce more NK cell death in vivo [32,34,37,38]. Furthermore, MR contrast agents released from NK cells in vivo may lead to non-specific signals from the free contrast agents [32,34].

Other imaging modalities have been used in some studies. Melder et al. used PET imaging to visualize activated NK cell infiltration into fibrosarcoma in a mouse model. Cells were labeled with $[^{11}C]$ methyl iodine and some of them were activated by interleukin (IL)-2. Activated and non-activated NK cells were injected into the lateral tail vein distal to the fibrosarcoma. PET imaging revealed no change in the migration of activated and non-activated NK cells at 30 min, while at 60 min a stronger tumor signal was obtained with the activated cells. PET imaging visualized accumulation of activated NK cells localized in small tumors [45]. PET provides advantages of excellent sensitivity and absolute quantification in a non-invasive setting, which is potentially applicable to clinical studies of cell delivery and localization [45–47].

SPECT imaging was used to visualize the migration of the allogenic NK cell to a tumor in renal cell carcinoma patients. To get an image of NK cells in the patients, the cells were labeled with $^{111}$In. Signals were obtained at two out of four large metastases [28]. SPECT imaging was also used to assess the in vivo migration of autologous NK cells to hepatic metastasis in colon cancer patients. Ex vivo expanded NK cells were labeled with $^{111}$In oxine and injected into hepatic artery of the patients. The injected NK cells were confined to the liver and spleen and accumulation of NK cells in malignant lesions was observed by SPECT. On the contrary, intravenously injected NK cells migrated to the lung, and then to the spleen, not to metastatic tissues [27]. A limitation of the study was the relatively low labeling efficiency of NK cells with $^{111}$In (less than 60 %) [27].

In another study, autoradiography was used to assess the migration of $[^{18}F]$fluorodeoxyglucose (FDG)-labeled genetically modified NK-92-scFv(FRP5)-zeta cells to HER2/neu-positive sarcoma in a mouse model. Tumor migration of the genetically modified cells was found to be two-fold higher compared to parental NK cells. Labeling efficiency was 81% after 60 min of incubation and cell viability was unaffected by the labeling protocol. However, in order to carry out NK cell monitoring for a longer duration the strategy should be selected [48]. Finally, Galli et al. demonstrated migration of NK cells using gamma camera imaging of NK cells labeled with $^{99m}$Tc-anti-CD56 monoclonal antibody. NK cells accumulated in anaplastic thyroid cancer within 24 h post-intravenous injection [35]. Nuclear imaging has slow acquisition time and labeling can be complicated [28,35,48]. Molecular imaging studies showing in vivo migration and infiltration of the NK cell to cancers are summarized in Table 1 and illustrated in Figures 1 and 2.
| Imaging Modality | Imaging | Method/Agent | Cell Type | Naïve/Modified Cell | Subject | Route of Injection | Duration | Migration/Infiltration to Tumor | Clinical Translation | Ref. |
|------------------|---------|-------------|-----------|---------------------|---------|-------------------|----------|-------------------------------|---------------------|-----|
| **Optical Imaging** | FLI | NIR dye | NK92MI Naïve | Mice | Intratumor | 24 h | Infiltrated to melanoma | Limited | [36] |
| | | Cy5.5 | NK92MI Naïve | Mice | Intravenous | Immediate | Migrated and Infiltrated to B cell lymphoma | Limited | [30] |
| | | DiD | Primary NK | Naïve | Mice | Intravenous | 5 days | Migrated to CXCL10 expressing melanoma | Limited | [17] |
| | | DiD | NK-92 | NK-92-sCFv (MOC31)-zeta | Mice | Intravenous | 1.5, 8 and 25 h | Migrated to EpCAM expressing prostate cancer | Limited | [40] |
| | | DiR | Primary NK | NRP-body | Mice | Intravenous | 5 days | Infiltrated to pancreatic cancer | Limited | [42] |
| | | DiR | Primary NK | Naïve | Mice | Intravenous | 0.5, 1, 2 and 4 h | Migrated to lung metastatic and xenograft breast cancer | Limited | [41] |
| **BLI** | | Fluc | NK92MI Naïve | Mice | Intravenous | 1, 3, 24 and 48 h | Migrated to lung metastatic thyroid cancer | Limited | [21] |
| | | Fluc | NK92MI Naïve | Mice | Intravenous | 1, 3, 24 and 48 h | Migrated to xenograft thyroid cancer | Limited | [21] |
| | | ferumoxides | NK-92 | NK-92-sCFv (MOC31)-zeta | Rat | Intraperitoneal | 1 and 24 h | Migrated to EpCAM expressing prostate cancer | Yes | [30] |
| | | ferucarbotran | NK-92 | NK-92-sCFv (FRP5)-zeta | Mice | Intravenous | 12 and 24 h | Migrated to HER2/neu positive NIH3T3 mammary tumors | Yes | [37] |
| | | USPIO | KHYG-1 | Naïve | Mice | Subcutaneous | 0-2 days | Infiltrated to neuroblastoma | Yes | [33] |
| | | USPIO | Primary NK | Naïve | Mice | Intratumor | 0-8 days | Infiltrated to Mantle cell lymphoma | Yes | [33] |
| | | USPIO | Primary NK | Naïve | Mice | Subcutaneous | 0-15 days | Infiltrated to melanoma | Yes | [33] |
| | | SPIO | NK92MI | Naïve | Rat | Intraarterial | Immediate | Infiltrated to hepatocellular carcinoma | Yes | [32] |
| **Magnetic Resonance Imaging** | MRI | ferumoxyl | LNK | Naïve | Rat | Intravenous and transcatheter | 1, 2 and 8 days | Migrated to hepatocellular carcinoma | Yes | [44] |
| | | ¹¹¹C | Murine NK | Naïve | Mice | Intravenous | 30, 60 min | Migrated to fibrosarcoma | Yes | [45] |
| | | ¹⁵³Tb | Primary NK | Naïve | human | Intravenous | 1.5-144 h | Migrated to renal cell carcinoma | Yes | [29] |
| | | ¹³¹I | Primary NK | Naïve | human | Intravenous | 6, 24, 72, 96 h | Liver metastases with colon carcinoma | Yes | [27] |
| **Nuclear Imaging** | SPECT | ¹¹¹In-oxyine | Primary NK | Naïve | human | Intravenous | 1-24 h | Migrated to thyroid cancer | Yes | [35] |
| | | ¹³¹In-oxyine | Primary NK | Naïve | mouse | Intravenous | 1-24 h | Migrated to thyroid cancer | Yes | [35] |
| | | ¹⁰⁹⁹Tc | Primary NK | Naïve | Mouse | Intravenous | 1-24 h | Migrated to thyroid cancer | Yes | [35] |

FLI, fluorescence imaging; BLI, bioluminescence imaging; MRI, magnetic resonance imaging; PET, positron-emission tomography; SPECT, single photon-emission computerized tomography; NIR, near infrared; SPIO, superparamagnetic iron oxide; USPIO: Ultrasound Superparamagnetic iron oxide; Fluc, firefly luciferase; AR, autoradiography; GC, gamma camera; NRP-body, NK-cell-recruiting protein-conjugated antibody.
4. Challenges in the NK Cell Expansion and Labeling

In the above reviewed studies, nine of the studies used the primary NK cells, followed by five studies with NK-92MI and four studies with NK-92. In addition, KHYG-1, LNK and murine NK cells were used by one study each (Table 1). Generally, the engineered NK cell lines (NK-92 or NK-92MI) are readily growing cells without Interleukin-2, when compared to primary NK cells [49]. Most preclinical and clinical studies using primary NK cells are derived from peripheral blood mononuclear cells (PBMCs), especially all the studies mentioned in this review. Primary NK cells represent only 10%
of the lymphocytes in the blood and obtaining functional NK cells is challenging [50]. Cell lines are mostly suitable for preclinical studies as reported and only NK-92 have been infused to advanced cancers patients with positives results and less side effects [51,52]. Further investigations are needed for successful NK cell-based therapies, such as developing a highly expanding, functional and clinically safe cell lines. Engineering to add chimeric antigen receptor (CAR) to primary NK cells and it revealed improve the therapeutic effects of NK cells and both NK cells and CAR modified NK cells are already in clinics [53,54]. In vivo fluorescent imaging of NK cells was mostly done by labeling of lipophilic dyes, after injection of dye labeled NK cells to animal/humans, division of NK cells dilutes imaging signals, whereas, in vivo optical imaging with transfection of reporter genes (such as luciferases) to NK cells does not reveal the signal dilution by cell division [17,21,42]. Therefore, reporter gene imaging can be suitable for studying the longevity of NK cells in vivo. However, genetic engineering of NK cells with a reporter gene is a laborious and difficult process. On the contrary, fluorescent imaging after direct dye labeling of NK cells is feasible and does not incur any genetics changes, therefore, the technique is suitable for a short-term study of small animals [55,56]. MR contrasts agents labeling also similar to that of fluorescent dye labeling, it could dilute the contrast agent upon cell division and signal persistence after cell death [32–34,43], in contrast signals of a reporter gene will disappear after cell death [57]. SPECT and PET imaging by radionuclides labeling to NK cells are available and decay of radioactivity limits long term in vivo imaging of NK cells [56,58].

5. Future Prospects of In Vivo NK Cell Imaging

Since each modality has its own limitations, multimodal hybrid imaging consisting of two or more imaging technologies can provide more informative results. Commercial systems integrating optical, PET, SPECT, CT and MR technologies in various combinations are already available. These hybrid techniques allow integration of the strengths of individual modalities. For example, recent advancement in tomographic fluorescence fusion systems allowed us to combine optimal imaging and high-resolution anatomical imaging techniques such as CT or MRI. This way, we can overcome the flaws in optical imaging approaches such as poor resolution. Likewise, a hybrid of PET and MRI can offer high sensitivity of PET and excellent resolution of MRI together, which are clinically relevant characteristics. Therefore, the hybrid imaging can be very useful for in vivo monitoring of NK cells in patients. These emerging developments can accelerate clinical application of promising NK cell-based therapies by accurate in vivo monitoring of administered therapeutic NK cells. Better in vivo NK cell monitoring should be possible with advancement of tracer chemistry and imaging technologies, which will ultimately progress the field of NK cell-based immunotherapy with further improvements in our understanding of genetic regulation in the NK cells.

6. Conclusions

Successful NK cell migration and infiltration relies on a variety of factors to ensure that NK cells reach the tumor and are able to eliminate it without being suppressed in the process. Continued studies on the intrinsic mechanisms of NK cell biology and regulation are warranted to develop more safe and efficient therapeutic strategies. Our knowledge of how NK cells migrate to tumors and other components of the immune system will continue to increase with the help of various molecular imaging technologies. This knowledge will contribute to the selection of the most suitable NK cell-based immunotherapy for certain clinical scenarios. Our capacity to design more effective personalized NK cell therapies will likely increase in the near future.

Author Contributions: P.G., R.L.R. and B.-C.A. contributed to the conception, writing, and discussion of this review manuscript. P.G. and R.L.R. wrote the initial draft of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2019R1I1A1A01061296).
Conflicts of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References
1. Sutlu, T.; Alici, E. Natural killer cell-based immunotherapy in cancer: Current insights and future prospects. *J. Intern. Med.* 2009, 266, 154–181. [CrossRef] [PubMed]
2. Cooper, M.A.; Colonna, M.; Yokoyama, W.M. Hidden talents of natural killers: NK cells in innate and adaptive immunity. *EMBO J.* 2009, 10, 1103–1110. [CrossRef] [PubMed]
3. Leung, W. Infusions of Allogeneic Natural Killer Cells as Cancer Therapy. *Clin. Cancer Res.* 2014, 20, 3390–3400. [CrossRef] [PubMed]
4. Guillerey, C.; Huntington, N.D.; Smyth, M.J. Targeting natural killer cells in cancer immunotherapy. *Nat. Immunol.* 2016, 17, 1025–1036. [CrossRef]
5. Albertsson, P.A.; Basse, P.H.; Hokland, M.; Goldfarb, R.H.; Nagelkerke, J.F.; Nannmark, U.; Kuppen, P.J.K. NK cells and the tumour microenvironment: Implications for NK-cell function and anti-tumour activity. *Trends Immunol.* 2003, 24, 603–609. [CrossRef]
6. Vitale, M.; Cantoni, C.; Pietra, G.; Mingari, M.C.; Moretta, L. Effect of tumor cells and tumor microenvironment on NK-cell function. *Eur. J. Immunol.* 2014, 44, 1582–1592. [CrossRef]
7. Vanherberghen, B.; Olofsson, P.E.; Forslund, E.; Sternberg-Simon, M.; Khorshidi, M.A.; Pacouret, S.; Guldevall, K.; Enqvist, M.; Malmberg, K.-J.; Mehr, R.; et al. Classification of human natural killer cells based on migration behavior and cytotoxic response. *Blood* 2013, 121, 1326–1334. [CrossRef]
8. Dong, R.; Ghosh, S.; Pappas, C.; Lu, X.; Zhu, M.; Zhu, J.; et al. Tumor-infiltrating lymphocytes and cancer. *Nature* 2013, 501, 274–282. [CrossRef]
9. Infante-Duarte, C.; Schreiber, R.D. NK cells and cancer. *Immunity* 2014, 41, 115–128. [CrossRef]
10. Rezvani, K.; Rouce, R.H. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer. *Front. Immunol.* 2015, 6. [CrossRef]
11. Garrod, K.R.; Wei, S.H.; Parker, I.; Cahalan, M.D. Natural killer cells actively patrol peripheral lymph nodes forming stable conjugates to eliminate MHC-mismatched targets. *Proc. Natl. Acad. Sci. USA* 2007, 104, 12081–12086. [CrossRef]
12. Fang, F.; Xiao, W.; Tian, Z. NK cell-based immunotherapy for cancer. *Semin. Immunol.* 2017. [CrossRef] [PubMed]
13. Lee, B.J.; Mace, E.M. Acquisition of cell migration defines NK cell differentiation from hematopoietic stem cell precursors. *bioRxiv* 2017, 142380. [CrossRef]
14. Somersalo, K.; Sakela, E. Fibronectin facilitates the migration of human natural killer cells. *Eur. J. Immunol.* 1991, 21, 35–42. [CrossRef]
15. Taub, D.D.; Sayers, T.J.; Carter, C.R.; Ortaldo, J.R. Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis. *J. Immunol.* 1995, 155, 3877–3888. [CrossRef]
16. Levi, I.; Amsalem, H.; Nissan, A.; Darash-Yahana, M.; Peretz, T.; Mandelboim, O.; Rachmilewitz, J. Characterization of tumor infiltrating natural killer cell subset. *Oncotarget* 2015, 6, 13835–13843. [CrossRef] [PubMed]
17. Wennerberg, E.; Kremer, V.; Childs, R.; Lundqvist, A. CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo. *Cancer Immunol. Immunother.* 2015, 64, 225–235. [CrossRef] [PubMed]
18. Kim, J.E.; Kalimuthu, S.; Ahn, B.-C. In vivo cell tracking with bioluminescence imaging. *Nucl. Med. Mol. Imaging* 2015, 49, 3–10. [CrossRef] [PubMed]
19. Kalimuthu, S.; Jeong, J.H.; Oh, J.M.; Ahn, B.-C. Drug Discovery by Molecular Imaging and Monitoring Therapy Response in Lymphoma. *Int. J. Mol. Sci.* 2017, 18, 1639. [CrossRef]
20. Lee, H.W.; Gangadaran, P.; Kalimuthu, S.; Ahn, B.-C. Advances in Molecular Imaging Strategies for In Vivo Tracking of Immune Cells. *BioMed Res. Int.* 2016, 2016, 1946855. [CrossRef]
21. Zhu, L.; Li, X.J.; Kalimuthu, S.; Gangadaran, P.; Lee, H.W.; Oh, J.M.; Baek, S.H.; Jeong, S.Y.; Lee, S.W.; Lee, J.; et al. Natural Killer Cell (NK-92MI)-Based Therapy for Pulmonary Metastasis of Anaplastic Thyroid Cancer in a Nude Mouse Model. *Front. Immunol.* 2017, 8, 816. [CrossRef]
22. Li, X.J.; Gangadaran, P.; Kalimuthu, S.; Oh, J.M.; Zhu, L.; Jeong, S.Y.; Lee, S.-W.; Lee, J.; Ahn, B.-C. Role of pulmonary macrophages in initiation of lung metastasis in anaplastic thyroid cancer. *Int. J. Cancer* 2016, 139, 2583–2592. [CrossRef] [PubMed]

23. Hillman, E.M.C.; Amoozegar, C.B.; Wang, T.; McCaslin, A.F.H.; Bouchard, M.B.; Mansfield, J.; Levenson, R.M. In vivo optical imaging and dynamic contrast methods for biomedical research. *Philos. Trans. A Math. Phys. Eng. Sci.* 2011, 369, 4620–4643. [CrossRef] [PubMed]

24. Lassailly, F.; Griessinger, E.; Bonnet, D. Microenvironmental contaminations induced by fluorescent lipophilic dyes used for noninvasive in vitro and in vivo cell tracking. *Blood* 2010, 115, 5347–5354. [CrossRef] [PubMed]

25. Zinn, K.R.; Chaudhuri, T.R.; Szafran, A.A.; O’Quinn, D.; Weaver, C.; Dugger, K.; Lamar, D.; Kesterson, R.A.; Wang, X.; Frank, S.J. Noninvasive bioluminescence imaging in small animals. *ILAR J.* 2008, 49, 103–115. [CrossRef]

26. Ahn, B.-C. Requisites for successful theranostics with radionuclide-based reporter gene imaging. *J. Drug Target.* 2014, 22, 295–303. [CrossRef] [PubMed]

27. Matera, L.; Galetto, A.; Bello, M.; Baiocco, C.; Chiappino, I.; Castellano, G.; Stacchini, A.; Satolli, M.A.; Mele, M.; Sandrucci, S.; et al. In vivo migration of labeled autologous natural killer cells to liver metastases in patients with colon carcinoma. *J. Transl. Med.* 2006, 4, 49. [CrossRef]

28. Meller, B.; Frohn, C.; Brand, J.-M.; Lauer, I.; Schelper, L.F.; von Hof, K.; Kirchner, H.; Richter, E.; Baehre, M. Monitoring of a new approach of immunotherapy with allogenic (111)In-labelled NK cells in patients with renal cell carcinoma. *Eur. J. Nucl. Med. Mol. Imaging* 2004, 31, 403–407. [CrossRef]

29. Rahmim, A.; Zaidi, H. PET versus SPECT: Strengths, limitations and challenges. *Nucl. Med. Commun.* 2008, 29, 193–207. [CrossRef]

30. Hengerer, A.; Grimm, J. Molecular magnetic resonance imaging. *Biomed. Imaging Interv. J.* 2006, 2, e8. [CrossRef]

31. Schick, F. Whole-body MRI at high field: Technical limits and clinical potential. *Eur. Radiol.* 2005, 15, 946–959. [CrossRef] [PubMed]

32. Sheu, A.Y.; Zhang, Z.; Omary, R.A.; Larson, A.C. MRI-monitored transcatheter intra-arterial delivery of SPIO-labeled natural killer cells to hepatocellular carcinoma: Preclinical studies in a rodent model. *Investig. Radiol.* 2013, 48, 492–499. [CrossRef] [PubMed]

33. Bouchlaka, M.N.; Ludwig, K.D.; Gordon, J.W.; Kutz, M.P.; Bednarz, B.P.; Fain, S.B.; Capitini, C.M. (19)F-MRI for monitoring human NK cells in vivo. *Oncoimmunology* 2016, 5, e1143996. [CrossRef] [PubMed]

34. Mallett, C.L.; McFadden, C.; Chen, Y.; Foster, P.J. Migration of iron-labeled KHYG-1 natural killer cells to subcutaneous tumors in nude mice, as detected by magnetic resonance imaging. *Cytoterapy* 2012, 14, 743–751. [CrossRef]

35. Galli, F.; Rapisarda, A.S.; Stabile, H.; Malviya, G.; Manni, L.; Bonanno, E.; Piaggio, G.; Gismondi, A.; Santoni, A.; Signore, A. In Vivo Imaging of Natural Killer Cell Tracking in Tumors. *J. Nucl. Med. Off. Publ. Soc. Nucl. Med.* 2015, 56, 1575–1580. [CrossRef]

36. Lim, Y.T.; Cho, M.Y.; Noh, Y.-W.; Chung, J.W.; Chung, B.H. Near-infrared emitting fluorescent nanocrystals-labeled natural killer cells as a platform technology for the optical imaging of immunotherapeutic cells-based cancer therapy. *Nanotechnology* 2009, 20, 475102. [CrossRef]

37. Daldrup-Link, H.E.; Meier, R.; Rudelius, M.; Piontek, G.; Piert, M.; Metz, S.; Settles, M.; Uherek, C.; Wels, W.; Schlegel, J.; et al. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. *Eur. Radiol.* 2005, 15, 4–13. [CrossRef]

38. Tavri, S.; Jha, P.; Meier, R.; Henning, T.D.; Knopp, C.; Piontek, G.; Piert, M.; Metz, S.; Settles, M.; Uherek, C.; Wels, W.; Schlegel, J.; et al. Optical imaging of cellular immunotherapy against prostate cancer. *Mol. Imaging* 2009, 8, 15–26. [CrossRef]
41. Uong, T.N.T.; Lee, K.-H.; Ahn, S.-J.; Kim, K.W.; Min, J.-J.; Hyun, H.; Yoon, M.S. Real-Time Tracking of Ex Vivo-Expanded Natural Killer Cells Toward Human Triple-Negative Breast Cancers. Front. Immunol. 2018, 9. [CrossRef] [PubMed]

42. Lee, J.; Kang, T.H.; Yoo, W.; Choi, H.; Jo, S.; Kong, K.; Lee, S.-R.; Kim, S.-U.; Kim, J.-S.; Cho, D.; et al. An Antibody Designed to Improve Adoptive NK-Cell Therapy Inhibits Pancreatic Cancer Progression in a Murine Model. Cancer Immunol. Res. 2019, 7, 219–229. [CrossRef] [PubMed]

43. Ruiz-Cabello, J.; Barnett, B.P.; Bottomley, P.A.; Bulte, J.W.M. Fluorine (19F) MRS and MRI in biomedicine. NMR Biomed. 2011, 24, 114–129. [CrossRef] [PubMed]

44. Su, Z.; Wang, X.; Zheng, L.; Lyu, T.; Figini, M.; Wang, B.; Procissi, D.; Shangguan, J.; Sun, C.; Pan, L.; et al. MRI-guided interventional natural killer cell delivery for liver tumor treatment. Cancer Med. 2018, 7, 1860–1869. [CrossRef]

45. Melder, R.J.; Brownell, A.L.; Shoup, T.M.; Brownell, G.L.; Jain, R.K. Imaging of activated natural killer cells in mice by positron emission tomography: Preferential uptake in tumors. Cancer Res. 1993, 53, 5867–5871.

46. Parashar, N.; Ahn, B.-C.; Ziv, K.; Ito, K.; Paulmurugan, R.; Willmann, J.K.; Chung, J.; Ikeno, F.; Swanson, J.C.; Merk, D.R.; et al. Multimodality Molecular Imaging of Cardiac Cell Transplantation: Part II. In Vivo Imaging of Bone Marrow Stromal Cells in Swine with PET/CT and MR Imaging. Radiology 2016, 280, 826–836. [CrossRef]

47. Townsend, D.W. Physical principles and technology of clinical PET imaging. Ann. Acad. Med. Singap. 2004, 33, 133–145.

48. Meier, R.; Piert, M.; Piontek, G.; Rudelius, M.; Oostendorp, R.A.; Senekowitsch-Schmidtke, R.; Henning, T.D.; Wels, W.S.; Uhrek, C.; Rummery, E.J.; et al. Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors. Nucl. Med. Biol. 2008, 35, 579–588. [CrossRef]

49. Zhang, J.; Zheng, H.; Diao, Y. Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy. Int. J. Mol. Sci. 2019, 20, 317. [CrossRef]

50. Klingemann, H.; Boissel, L.; Toneguzzo, F. Natural Killer Cells for Immunotherapy—Advantages of the NK-92 Cell Line over Blood NK Cells. Front. Immunol. 2016, 7, 91. [CrossRef]

51. Williams, B.A.; Law, A.D.; Routy, B.; denHollander, N.; Gupta, V.; Wang, X.-H.; Chaboureaux, A.; Viswanathan, S.; Keating, A. A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. Oncotarget 2017, 8, 89256–89268. [CrossRef] [PubMed]

52. Arai, S.; Meagher, R.; Swearingen, M.; Myint, H.; Rich, E.; Martinson, J.; Klingemann, H. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: A phase I trial. Cytotherapy 2008, 10, 625–632. [CrossRef] [PubMed]

53. Burger, M.C.; Zhang, C.; Harter, P.N.; Romanski, A.; Strassheimer, F.; Senft, C.; Tonn, T.; Steinbach, J.P.; Wels, W.S. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy. Front. Immunol. 2019, 10. [CrossRef] [PubMed]

54. Wang, W.; Jiang, J.; Wu, C. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects. Cancer Lett. 2020, 472, 175–180. [CrossRef] [PubMed]

55. Jha, P.; Golovko, D.; Bains, S.; Hostetter, D.; Meier, R.; Wendland, M.F.; Dale, R.; Link, K.H. Monitoring of natural killer cell immunotherapy using noninvasive imaging modalities. Cancer Res. 2010, 70, 6109–6113. [CrossRef]

56. Gangadaran, P.; Ahn, B.-C. Molecular Imaging: A Useful Tool for the Development of Natural Killer Cell-Based Immunotherapies. Front. Immunol. 2017, 8. [CrossRef]

57. Scarfe, L.; Taylor, A.; Sharkey, J.; Harwood, R.; Barrow, M.; Comenge, J.; Beeken, L.; Astley, C.; Santeramo, L.; Hutchinson, C.; et al. Non-invasive imaging reveals conditions that impact distribution and persistence of cells after in vivo administration. Stem Cell Res. Ther. 2018, 9, 332. [CrossRef]

58. Shapovalova, M.; Pyper, S.R.; Moriarity, B.S.; LeBeau, A.M. The Molecular Imaging of Natural Killer Cells. Mol. Imaging 2018, 17. [CrossRef]